ClinicalTrials.gg
Not yet recruitingNCT07942012PHORARUpdated Nov 17, 2026

PHORA-USE Registry (PHORAR)

An observational study in Pulmonary Arterial Hypertension, sponsored by Sentara Norfolk General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sentara Norfolk General Hospital · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
650
Ages
1 Day and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 39 open to participants now, 57 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
17th of 60
650 · median 73
Started
2027
the only one that year
Observational
60 of 313
11 open now
Primary completion
2031-01
later than 53 of 56 live
Registered
313th of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 17th largest by planned enrollment of the 60 observational ones that give a count, is the only one that started in 2027, is one of 60 observational ones, reaches primary completion later than 53 of the 56 other live ones, and was the 313th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

39 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Day and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with significant illness and reduced survival. The PHORA-USE Registry (PHORAR) is a prospective, multicenter observational registry designed to collect real-world clinical data from adult and pediatric patients with PAH receiving routine clinical care. The purpose of this registry is to create a centralized database that can be used to better understand patient characteristics, treatment patterns, disease progression, and clinical outcomes. Information collected through the registry will support observational analyses aimed at identifying factors associated with outcomes and may contribute to the development of improved risk assessment and treatment strategies for patients with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • Registry
04

Who can participate

Ages eligible
1 Day and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult and pediatric patients with pulmonary arterial hypertension (PAH) receiving care at participating pulmonary hypertension centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, including adults (≥18 years) and pediatric participants (1 day to \<18 years of age).
  • Diagnosed with pulmonary arterial hypertension (PAH) within the first year of diagnosis or treatment, or treatment-naïve.
  • Diagnosis of PAH classified as WHO Pulmonary Hypertension Group I (pediatric participants may include Group III), including idiopathic PAH, heritable PAH, and PAH associated with collagen vascular disease, drugs, congenital heart disease, cirrhosis, or .
  • Right heart catheterization (RHC) demonstrating:
  • Mean pulmonary arterial pressure (mPAP) ≥20 mm Hg
  • Pulmonary capillary wedge pressure (PCWP) ≤18 mm Hg or left ventricular end-diastolic pressure (LVEDP) ≤15 mm Hg
  • Pulmonary vascular resistance (PVR) ≥2 Wood units
  • Exceptions to RHC requirements may be permitted in certain pediatric participants at the discretion of the site Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  • Adult participants with pulmonary hypertension classified as WHO Pulmonary Hypertension Groups II, III, IV, or V.
  • Pediatric participants with pulmonary hypertension classified as WHO Pulmonary Hypertension Groups II, IV, or V.
  • Pregnant or nursing women.
  • Children with a diagnosis of diaphragmatic hernia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
650 participants (estimated)
Patient registry
No

Groups and cohorts

  • PHORA-USE Registry Cohort

    Adult and pediatric patients with pulmonary arterial hypertension (PAH) enrolled in the PHORA-USE Registry (PHORAR). Participants will receive routine clinical care as determined by their treating clinicians. Clinical data will be collected from existing medical records and standard-of-care documentation and followed longitudinally for observational analyses of patient characteristics, treatment patterns, disease progression, and outcomes.

    Other: Routine Clinical Care

Interventions

  • OtherRoutine Clinical Care

    Participants receive routine clinical care for pulmonary arterial hypertension as determined by their treating clinicians. No drugs, devices, procedures, diagnostic tests, or clinical interventions are assigned by the study protocol. The only research activity is abstraction of data from existing medical records for inclusion in the registry.

06

What researchers measure

Primary outcomes

  1. Overall survival among participants with pulmonary arterial hypertension

    Assessment of overall survival among adult and pediatric participants with pulmonary arterial hypertension enrolled in the PHORA-USE Registry

    Time frame: Up to 4 years

Secondary outcomes

  1. Number of participants who underwent organ transplantation (lung, heart-lung, heart, lung-liver, or lung-kidney)

    Occurrence of transplantation as documented in the electronic health record. Transplant type is recorded as one of: lung transplant, heart-lung transplant, heart transplant, lung-liver transplant, or lung-kidney transplant. Reported as the cumulative count of participants who received any transplant during the observation period.

    Time frame: Up to 4 years

  2. Number of deaths by cause of death category among participants with pulmonary arterial hypertension

    Among participants who are deceased, cause of death is recorded using a standardized checklist (right heart failure, sudden cardiac death, cardiogenic shock, malignancy, renal failure, pulmonary hypertension, pulmonary infection, respiratory failure, sepsis/multi-organ failure, transplant-related, unknown, or other). Multiple causes may be selected per decedent; results are reported as the number of deaths attributed to each cause category over the observation period (a single participant may contribute to more than one category).

    Time frame: Up to 4 years

  3. Number of pulmonary hypertension-related hospitalizations per participant

    Count of inpatient hospitalizations attributed to pulmonary hypertension as documented in the electronic health record. PH-relatedness is determined by the treating clinician and recorded as yes/no. PH-related reasons include right heart failure, cardiogenic shock, worsening pulmonary hypertension, arrhythmia, infection, or transplant. Reported as the number of PH-related hospitalizations per participant.

    Time frame: Up to 4 years

  4. Number of pulmonary hypertension-related hospitalizations and observation stays per participant

    Count of inpatient hospitalizations and observation stays attributed to pulmonary hypertension as documented in the electronic health record. PH-relatedness is determined by the treating clinician and recorded as yes/no. PH-related reasons include right heart failure, cardiogenic shock, worsening pulmonary hypertension, arrhythmia, infection, or transplant. Reported as the combined number of PH-related inpatient hospitalizations and observation stays per participant.

    Time frame: Up to 4 years

  5. Number of emergency department visits per participant

    Count of emergency department visits (encounter type = "Emergency Department Visit") as documented in the electronic health record during the observation period. PH-relatedness of each visit is recorded. Reported as the number of ED visits per participant.

    Time frame: Up to 4 years

  6. Number of participants receiving each PAH-specific drug therapy regimen (monotherapy, dual, or triple combination) at baseline and at each annual follow-up

    PAH-specific medications are recorded by drug class (endothelin receptor antagonist, PDE5 inhibitor, prostacyclin, guanylate cyclase agonist, calcium channel blocker, tyrosine kinase inhibitor, activin pathway inhibitor, or combination pill \[macitentan + tadalafil\]), medication name, dose, frequency, route, start date, and stop date. Treatment regimen intensity is derived from the number of concurrent PAH-specific drug classes prescribed to each participant. Reported as the number of participants on monotherapy (1 class), dual therapy (2 classes), or triple/higher combination therapy (≥3 classes) at baseline and at each annual follow-up.

    Time frame: Up to 4 years

  7. Number of participants with each type of clinical management change at each follow-up visit

    Clinical management changes are recorded at each visit using a standardized checklist of 22 categories including: hospitalization for PAH/heart failure management, transplant evaluation initiated, listed for transplant, new PAH medication class initiated, prostacyclin therapy titrated, palliative care consultation, and others. Reported as the number of participants with each management change category at each follow-up.

    Time frame: Up to 4 years

  8. Number of participants whose treatment changes were primarily driven by each driver category at each follow-up visit

    At each visit, the primary driver of treatment changes is recorded from a standardized list of 18 categories including: risk score (PHORA, REVEAL 2.0, REVEAL Lite 2), clinical assessment (gestalt), six-minute walk distance, cardiopulmonary exercise testing, NYHA functional class, echocardiography findings, cardiac MRI findings, natriuretic peptide levels, renal function, hepatic function, other biomarkers, chest X-ray, CT imaging, medication side effects, quality of life assessment, patient or caregiver preference, other, or none. Secondary drivers are also recorded. Reported as the number of participants whose treatment changes were primarily driven by each category at each follow-up.

    Time frame: Up to 4 years

  9. Number of participants enrolled at sites that use PAH risk stratification in routine clinical care versus sites that do not

    Each participating site reports whether PAH risk stratification is used as part of routine clinical care (yes/no). Reported as the number of participants enrolled at risk-stratification sites compared with the number enrolled at non-risk-stratification sites. This grouping variable enables comparison of clinical outcomes between the two site types.

    Time frame: Up to 4 years

  10. PHORA risk score value at each follow-up visit among participants at sites using risk stratification

    The PHORA risk score (expressed as a percentage) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean PHORA risk score (%) at baseline and at each annual follow-up.

    Time frame: Up to 4 years

  11. REVEAL 2.0 risk score at each follow-up visit among participants at sites using risk stratification

    The REVEAL 2.0 risk score (numeric) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean REVEAL 2.0 score at baseline and at each annual follow-up.

    Time frame: Up to 4 years

  12. REVEAL Lite 2.0 risk score at each follow-up visit among participants at sites using risk stratification

    The REVEAL Lite 2.0 risk score (numeric) is recorded from the clinical decision support system at each visit at sites that use PAH risk stratification in routine clinical care. Reported as the mean REVEAL Lite 2.0 score at baseline and at each annual follow-up.

    Time frame: Up to 4 years

07

Study locations

1 site
  • Sentara Pulmonary Arterial Hypertension Clinic
    Norfolk, Virginia 23507, United States
    • Raymond Benza, MD · Contactrxbenza@sentara.com · 757-388-9138
    • Raymond Benza, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — The study team has not yet made a final determination regarding the sharing of individual participant data. Any future data-sharing plans will be evaluated in accordance with applicable privacy regulations, institutional policies, participant consent, and data use agreements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2031, 48 months later.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 48 months is below that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2031
CompletionEst.
Jan 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942012
Lead sponsor
Sentara Norfolk General Hospital
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2031 (estimated)
Completion
Jan 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Priscilla Correa-Jaque, MTDA
Contact
pxcorrea@sentara.com
757-388-9138
Raymond L Benza, MD
principal investigator · Sentara Norfolk General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion